CD137-Targeted Therapy Market Set for Growth as Novel Therapeutic Approaches, Advanced Technology Platforms and Expanding Clinical Trials Unlock New Opportunities Through 2026
Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026" has been added to ResearchAndMarkets.com's offering.
Report Highlights
Growing Need for CD137-Targeted Therapies
CD137, also known as 4-1BB, is a co-stimulatory receptor involved in T-cell activation, survival and expansion. Its capacity to enhance antitumor immune responses has established CD137 as an important target in cancer immunotherapy research. Despite substantial advances in immuno-oncology, chemotherapy, immune checkpoint inhibitors and other established treatments continue to demonstrate limitations in efficacy, durability and patient response, particularly in several solid tumor indications.
CD137-targeted therapies are being investigated for their potential to stimulate immune activity within the tumor microenvironment and strengthen antitumor responses. The report examines the expanding CD137-targeted therapies market and pipeline, covering ongoing clinical trials, emerging therapeutic approaches, proprietary technology platforms and the companies driving innovation. It also evaluates the scientific, clinical and competitive factors expected to influence the future commercialization of CD137-targeted treatments.
CD137-Targeted Therapies Clinical Trial Analysis
The report provides a detailed assessment of more than 90 CD137-targeted therapies across multiple stages of clinical development. Clinical trial analysis is segmented by company, country, indication and phase, with the most advanced programs reaching Phase III. The pipeline includes programs targeting solid tumors and hematological malignancies, offering stakeholders a comprehensive view of current research priorities and development activity.
Combination treatment strategies represent a significant area of clinical investigation. CD137 agonists and related agents are being evaluated alongside chemotherapy, immune checkpoint inhibitors and targeted treatments, including PD-1 and VEGF inhibitors. These studies are designed to determine whether combination regimens can improve response rates, treatment durability and clinical outcomes compared with monotherapy. The report reviews emerging safety and efficacy findings, development challenges and evidence shaping future clinical strategies.
Proprietary Technology Platforms
Technology innovation is central to the development of next-generation CD137-targeted therapies. The report profiles proprietary platforms intended to increase tumor selectivity, enhance therapeutic activity and reduce systemic toxicity. Among the featured technologies is AP Biosciences' T-cube platform, which supports the development of bispecific antibodies designed to activate CD137-mediated T-cell responses following engagement with tumor-associated antigens.
These platforms may help address safety concerns associated with immune activation, including cytokine release and off-target effects. The report assesses the strategic importance of bispecific antibodies, targeted delivery systems and other emerging modalities within the evolving CD137-targeted therapy pipeline.
Leading Companies Developing CD137-Targeted Therapies
The competitive landscape includes established pharmaceutical companies and emerging biotechnology developers. Roche, Genmab and Sichuan Baili Pharmaceutical are among the companies advancing CD137-targeted candidates through clinical development. ABL Bio, Pieris Pharmaceuticals and other specialized biotechnology companies are contributing additional innovation through bispecific antibody formats, differentiated delivery technologies and novel combination strategies.
The report profiles leading participants, pipeline assets, clinical progress, research partnerships and development strategies. This analysis provides insight into competitive positioning and the organizations expected to shape the global CD137-targeted therapies market.
Future Outlook for the CD137-Targeted Therapies Market
The first commercial launch of a CD137-targeted therapy is expected by 2030, supported by continued clinical progress and investment in next-generation immuno-oncology platforms. Future development is likely to focus on improving tumor-specific immune activation, overcoming immune resistance and reducing adverse events such as cytokine release syndrome.
Combination regimens involving CD137 agonists, checkpoint inhibitors and targeted therapies could become increasingly important as new clinical evidence emerges. By examining clinical, technological, competitive and commercial trends, the report enables pharmaceutical companies, biotechnology developers, investors and other stakeholders to assess opportunities and anticipate the future direction of the global CD137-targeted therapies landscape.
Key Topics Covered:
1. Research Methodology
2. Brief Introduction to CD137
2.1 Clinical Overview
2.2 Biological History of CD137
2.3 CD137 Hosting an Era of Agonists Over Antagonists
2.4 Bi-Directional Signaling in CD137
3. Global CD137 Targeted Therapy Market Outlook
3.1 Current Research & Market Scenario
3.2 Future Commercialization Opportunities
4. CD137 Targeted Therapy Clinical Innovation Trends by Region
4.1 China
4.2 South Korea
4.3 US
4.4 Europe
4.5 Australia
5. CD137 Role & Clinical Progress by Indication
5.1 Cancer
5.1.1 Leukemia
5.1.2 Lymphoma
5.1.3 Lung Cancer
5.1.4 Melanoma
5.1.5 Breast Cancer
5.1.6 Colorectal Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Microbial Infections
5.4 Neuronal Diseases
6. Global CD137 Targeted Therapies Clinical Trials Overview
6.1 by Company
6.2 by Country
6.3 by Indication
6.4 by Phase
7. CD137 Targeted Therapies Clinical Trials Insight by Company, Country, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III
8. CD137 Targeted Therapy Proprietary Technology Platforms by Companies
9. Therapeutic Approaches for Targeting CD137
9.1 Antibodies
9.1.1 Monoclonal antibodies
9.1.2 Bispecific Antibody Centered Approaches
9.1.3 Trispecific Antibody Established Strategies
9.1.4 Tetraspecific Antibody Strategies
9.1.5 Single-chain variable fragments
9.2 Peptides
9.3 Protein-Based Therapeutics
10. Combination Therapies with CD137 Targeted Therapy
11. Competitive Landscape
11.1 ABL Bio
11.2 Adagene
11.3 Alligator Bioscience
11.4 BeOne Medicines
11.5 Bicycle Therapeutics
11.6 BioNTech
11.7 Crescendo Biologics
11.8 Compass Therapeutics
11.9 Eutilex
11.10 F-star Therapeutics
11.11 Genmab
11.12 NovaBridge Biosciences
11.13 Kyinno Biotechnology
11.14 Lyvgen Biopharma
11.15 Obsidian Therapeutics
11.16 OriCell Therapeutics
11.17 Palvella Therapeutics
11.18 Shanghai Henlius Biotech
11.19 Sichuan Baili Pharmaceutical
11.20 SystImmune
List of Tables
Table 2-1: CD137 Expression Across Cell Types
Table 2-2: Comparison of Antagonistic vs Agonistic Immunotherapies
Table 5-1: Lymphoma - Clinical Trials Underway for GNC-038 & GNC-035
Table 9-1: Some Bispecific Antibodies Targeting CD137 in Development
Table 9-2: Some Trispecific Antibodies Targeting CD137 in Development
Table 9-3: Some Tetraspecific Antibodies Targeting CD137 in Development
Table 10-1: Ongoing Clinical Trials Evaluating CD137 Antibody Combinations
List of Figures
Figure 2-1: Evolution of Cancer Immunotherapy Approaches
Figure 2-2: Biological Effects Triggered by CD137 Stimulation
Figure 2-3: CD137 - Discovery & Early Biological Characterization
Figure 2-4: Mechanistic Pathways Triggered by CD137 Ligation
Figure 2-5: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms
Figure 2-6: Why CD137 Became An Important Target
Figure 2-7: Schematic Depiction of Bidirectional Signaling by CD137-CD137L
Figure 2-8: CD137 - Forward Signaling Cascade in Immune Cells
Figure 2-9: CD137L - Reverse Signaling
Figure 2-10: Bidirectional Signaling Loop Between CD137 & CD137L
Figure 3-1: Global CD137 Targeting Therapy Market - Future Opportunities
Figure 5-1: Bidirectional CD137-CD137L Signaling in Leukemia Cell Survival
Figure 5-2: GNC-035-105 Phase Ib/II (NCT05944978) Study - Initiation & Completion Year
Figure 5-3: GNC-035-105 Phase I (NCT05944978) Study - Initiation & Completion Year
Figure 5-4: GNC-038-101 Phase I (NCT04606433) Study - Initiation & Completion Year
Figure 5-5: Lymphoma - CD137's Role in Countering Immune Evasion
Figure 5-6: BP41072 Phase I/II (NCT04077723) Study - Initiation & Completion Year
Figure 5-7: YH004003 Phase I (NCT05564806) Study - Initiation & Completion Year
Figure 5-8: IBD0333-101 Phase I/II (NCT06292208) Study - Initiation & Completion Year
Figure 5-9: Lung Cancer - Rationale for Targeting CD137
Figure 5-10: BT7480-100 Phase I/II (NCT05163041) Study - Initiation & Completion Year
Figure 5-11: GCT1046-04 Phase 2 (NCT05117242) Study - Initiation & Completion Year
Figure 5-12: HLX35-FIH101 Phase I (NCT05360381) Study - Initiation & Completion Year
Figure 5-13: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation & Completion Year
Figure 5-14: Melanoma - CD137 as a Costimulatory Driver of Disease Immunity
Figure 5-15: FS222-19101 Phase I (NCT04740424) Study - Initiation & Completion Year
Figure 5-16: LBL-024-CN007 Phase I/II (NCT07099430) Study - Initiation & Completion Year
Figure 5-17: ABBIL1TY MELANOMA-07 Phase II (NCT06984328) Study - Initiation & Completion Year
Figure 5-18: Breast Cancer - Dual Role of CD137 in Disease Biology
Figure 5-19: BT7480-100 Phase I/II (NCT05163041) Study - Initiation & Completion Year
Figure 5-20: AP402-101 Phase I/II (NCT06669975) Study - Initiation & Completion Year
Figure 5-21: AVIATOR Phase 2 (NCT03414658) Study - Initiation & Completion Year
Figure 5-22: ADG106-T6002 Phase 1/2 (NCT05275777) Study - Initiation & Completion Year
Figure 5-23: YH32367-101 Phase I/II (NCT05523947) Study - Initiation & Completion Year
Figure 5-24: GNC-035-103 Phase I (NCT05160545) Study - Initiation & Completion Year
Figure 5-25: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation & Completion Year
Figure 5-26: NCI-2018-01036 Phase 1 (NCT03290937) Study - Initiation & Completion Year
Figure 5-27: 1002-CL-0101 Phase I (NCT05719558) Study - Initiation & Completion Year
Figure 5-28: BNT314-02 Phase I/II (NCT07079631) Study - Initiation & Completion Year
Figure 5-29: CD137 - Dual Role in Immune Regulation
Figure 5-30: Microbial Infections - CD137 Expression & Immune Roles
Figure 5-31: CD137 in Neuroinflammation
Figure 6-1: Global - CD137 Targeted Therapies Clinical Pipeline by Company (Numbers), 2026
Figure 6-2: Global - CD137 Targeted Therapies Clinical Pipeline by Country (Numbers), 2026
Figure 6-3: Global - CD137 Targeted Therapies Clinical Pipeline by Indication (Numbers), 2026
Figure 6-4: Global - CD137 Targeted Therapies Clinical Pipeline by Phase (Numbers), 2026
Figure 8-1: Adagene - Anti CD137 NEObody ACG106
Figure 8-2: Adagene - Anti CD137 POWERbody ADG206
Figure 8-3: Genmab - DUObody Production Process
Figure 8-4: Genmab - DUObody Platform Detail
Figure 8-5: Crescendo Biologics - Humabody Structure
Figure 8-6: CB307 Humabody - Structure
Figure 8-7: Numab Therapeutics - MATCH Format
Figure 8-8: NM21-1480 - Structure
Figure 8-9: Systimmune - GNC-039 Structure
Figure 8-10: Systimmune - GNC-035 Structure
Figure 8-11: Systimmune - GNC-038 Structure
Figure 8-12: Merus - Multiclonics Structure
Figure 8-13: Chugai Pharmabody Research - Dual-Ig Technology
Figure 8-14: Eutilex - Costim Platform Technology
Figure 8-15: aND-Body - Ampersand Biomedicines
Figure 8-16: X-body Platform - Leads Biolabs
Figure 8-17: T-cube Bispecific Antibody Platform - AP Biosciences
Figure 8-18: Grabody-T - ABL Bio
Figure 8-19: LEAD-452 Trimerbody - Structure
Figure 9-1: ATOR-1017 - Mechanism of Action
Figure 9-2: EU101 - Mode of Action
Figure 9-3: LVGN6051 - Mechanism of Action
Figure 9-4: Ragistomig - Structure & Mechanism of Action
Figure 9-5: FS120 - Improving PD-1 & Chemotherapy Responses
Figure 9-6: FS222 - Structure
Figure 9-7: FS222 - Mechanism of Action
Figure 9-8: MP0310 - Mechanism of Action
Figure 9-9: CD137 Targeting GNC Tetraspecific Antibodies
Figure 9-10: CD137 Targeting Peptide - Mechanism
Figure 9-11: CD137 Targeting Fusion Protein - Conditional Activation Design
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/x2s776
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.